Drug name - Talzenna

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8420650 PFIZER Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP)
Jul, 2029

(6 years from now)

US8012976 PFIZER Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP)
Oct, 2029

(7 years from now)

US10189837 PFIZER Crystalline (8S,9R)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one tosylate salt
Oct, 2031

(9 years from now)

US8735392 PFIZER Crystalline (8S,9R)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one tosylate salt
Oct, 2031

(9 years from now)

CN104478875A PFIZER Dihydro Pyridine Phthalocyanine Triazine Ketone Inhibitor Of Poly (Adp-Ribose) Polymerase (Parp)
Jul, 2029

(6 years from now)

CN102171214A PFIZER Dihydropyridophthalazinone Inhibitors Of Poly(Adp-Ribose)Polymerase (Parp)
Jul, 2029

(6 years from now)

CN102171214B PFIZER Poly (Adp-Ribose) Polymerase (Parp) And Dihydro Pyridine Phthalocyanine And Triazine Ketone Inhibitor
Jul, 2029

(6 years from now)

CN104478875B PFIZER Poly (Adp-Ribose) Polymerase (Parp) Dihydropyridine And Phthalazinone Inhibitors
Jul, 2029

(6 years from now)

CN103282365B PFIZER Crystalline Toluenesulfonate Of (8S,9R)-5-Fluoro-8-(4-Fluorophenyl)-9-(1-Methyl-1H-1,2,4-Triazol-5-Yl)-8,9-Dihydro-2H-Pyrido[4,3,2-De]Phthalazine-3-(7H)-One
Oct, 2031

(9 years from now)

CN103282365A PFIZER Crystals Of (8S, 9R) -5-(4 - (-8 - Fluorophenyl) -9-(1-Methyl - -1H-1, 2, 4-Triazole - -5 - Group) - 9, -8 - Dihydro - -2H - Pyrido [4 3, 2-De] Phthalazine -3 (7H) - Ketone Tosylate
Oct, 2031

(9 years from now)

IN298469B PFIZER Dihydropyridophthalazinone Inhibitors Of Poly(Adpribose) Polymerase (Parp)
Jul, 2029

(6 years from now)

EP2326650B9 PFIZER Dihydropyridophthalazinone Inhibitors Of Poly(Adp-Ribose)Polymerase (Parp)
Jul, 2029

(6 years from now)

EP2326650A4 PFIZER Dihydropyridophthalazinone Inhibitors Of Poly(Adp-Ribose)Polymerase (Parp)
Jul, 2029

(6 years from now)

EP2326650A2 PFIZER Dihydropyridophthalazinone Inhibitors Of Poly(Adp-Ribose)Polymerase (Parp)
Jul, 2029

(6 years from now)

EP2326650B1 PFIZER Dihydropyridophthalazinone Inhibitors Of Poly(Adp-Ribose)Polymerase (Parp)
Jul, 2029

(6 years from now)

EP2767537B1 PFIZER Dihydropyridophthalazinone Inhibitors Of Poly(Adp-Ribose)Polymerase (Parp)
Jul, 2029

(6 years from now)

EP2767537A1 PFIZER Dihydropyridophthalazinone Inhibitors Of Poly(Adp-Ribose)Polymerase (Parp)
Jul, 2029

(6 years from now)

EP2630146B1 PFIZER Crystaline (8S,9R)-5-Fluoro-8-(4-Fluorophenyl)-9-(1-Methyl-1H-1,2,4-Triazol-5-Yl)-8,9-Dihydro-2H-Pyrido[4,3,2-De]Phtalazin-3(7H)-One Tosylate Salt
Oct, 2031

(9 years from now)

EP2630146A1 PFIZER Crystaline (8S,9R)-5-Fluoro-8-(4-Fluorophenyl)-9-(1-Methyl-1H-1,2,4-Triazol-5-Yl)-8,9-Dihydro-2H-Pyrido[4,3,2-De]Phtalazin-3(7H)-One Tosylate Salt
Oct, 2031

(9 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9820985 PFIZER Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP) Jul, 2029

(6 years from now)

Drugs and Companies using TALAZOPARIB TOSYLATE ingredient

Treatment: Treatment of adult patients with deleterious or suspected deleterious germline breast cancer susceptibility gene (brca)-mutated (gbrcam) human epidermal growth factor receptor 2 (her2)-negative locally advanced or metastatic breast cancer

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 0.25MG BASE CAPSULE;ORAL Prescription
EQ 0.5MG BASE CAPSULE;ORAL Prescription
EQ 0.75MG BASE CAPSULE;ORAL Prescription
EQ 1MG BASE CAPSULE;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.